Valneva (VALN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Valneva SE has reported steady financial results for the first half of 2024, with total revenues of €70.8 million and a net profit of €34.0 million, reflecting a strong recovery from the previous year’s losses. The company has confirmed its full-year revenue guidance, expecting between €170 million and €190 million, and has successfully expanded its strategic pipeline, including the acquisition of an exclusive license for a Phase 2 Shigella vaccine candidate. Moreover, Valneva’s chikungunya vaccine, IXCHIQ®, is gaining traction with new authorizations in Europe and Canada and anticipated label expansions.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.